Almaject Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Almaject Inc Pharmaceutical Import Records from India — 2 Products, $2.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Almaject Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $2.0M Trade | TransData Nexus

Almaject Inc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $2.0M Total Trade · DGFT Verified

Almaject Inc is a pharmaceutical importer based in United States with a total trade value of $2.0M across 2 products in 2 therapeutic categories. Based on 41 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Almaject Inc sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Almaject Inc — Import Portfolio & Supplier Network

Almaject Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Almaject Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$2.9M	61	100.0%

Almaject Inc sources from 1 verified Indian supplier across 15 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Almaject Inc Import?

Formulation	Value	Ships
Vancomycin hydrochloride for injection	$883.1K	19
Ketorolac tromethamine injection USP	$630.9K	13
Ketorolac tromethamine injection USP	$400.0K	8
Labetalol hydrochloride injection USP	$200.0K	4
Caspofungin acetate for injection	$150.0K	3
Labetalol hydrochloride injection USP	$102.2K	3
Rocuronium bromide injection 100MG/10ML	$100.0K	2
Metoprolol tartrate injection USP 5MG	$76.5K	2
Rocuronium bromide injection 10MG/ML	$50.0K	1
Ketorolac tromethamine injection USP	$50.0K	1
Tranexamic acid injection 100MG/ML, 10ML	$50.0K	1
Dexrazoxane for injection 500MG/vial	$50.0K	1
Caspofungin acetate for injection	$50.0K	1
Labetalol hcl injection USP 100MG/20ML	$50.0K	1
Labetalol hcl injection USP 200MG/40ML	$25.5K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ketorolac	Analgesics & Antipyretics	$1.1M	22	0.9%	6
2	Vancomycin	Antibiotics	$950.0K	19	1.0%	11

Almaject Inc imports 2 pharmaceutical products across 2 categories into United States totaling $2.0M.

Almaject Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Almaject Inc. is a U.S.-based pharmaceutical company specializing in the commercialization of generic injectable medications for the acute and alternate site healthcare markets. Established in 2020, Almaject operates as an affiliate of Alvogen, a global, privately owned pharmaceutical company focused on the development, manufacturing, and commercialization of generic, brand, over-the-counter (OTC), and biosimilar products worldwide.

Headquartered in Morristown, New Jersey, Almaject leverages Alvogen's extensive infrastructure, including a manufacturing facility in Norwich, New York, which produces a diverse range of dosage forms such as solid oral dosages, soft gelatin capsules, modified release tablets, transdermals, creams, ointments, and injectables. This strategic positioning enables Almaject to effectively serve the U.S. pharmaceutical distribution network, focusing on the acute and alternate site healthcare sectors.

2Distribution Network

Almaject's distribution network is primarily centered in the United States, with its manufacturing operations based in Norwich, New York. This facility is equipped to produce a wide array of pharmaceutical products, including injectables, which are then distributed to various healthcare providers across the country. While specific warehouse locations and logistics capabilities are not publicly detailed, Almaject's affiliation with Alvogen suggests access to a robust distribution infrastructure capable of supporting nationwide coverage.

3Industry Role

Within the U.S. pharmaceutical supply chain, Almaject Inc. functions as a pharmaceutical importer and distributor, focusing on the commercialization of generic injectable products. By sourcing these products from international manufacturers, including those in India, Almaject plays a pivotal role in enhancing the availability of cost-effective injectable medications in the U.S. market. This positioning allows Almaject to address the needs of acute and alternate site healthcare providers by offering a diverse portfolio of generic injectables.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Almaject Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Almaject's sourcing strategy exhibits a high degree of concentration, with a total import value of $2.0 million USD from India across 41 shipments, all sourced from a single supplier, GLAND PHARMA LIMITED. This supplier concentration indicates a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chain logistics. However, this dependency also introduces risks related to supply chain disruptions, regulatory changes, or quality control issues at the supplier's end. The absence of alternative suppliers in Almaject's sourcing profile suggests a need for strategic diversification to mitigate potential risks.

2Supply Chain Resilience

Almaject's supply chain resilience is closely tied to its exclusive relationship with GLAND PHARMA LIMITED. The lack of backup suppliers and limited formulation diversity may expose Almaject to vulnerabilities in the event of supply chain disruptions or regulatory challenges affecting GLAND PHARMA LIMITED. Additionally, the concentration of shipments from a single supplier could lead to challenges in maintaining consistent product quality and availability. To enhance supply chain resilience, Almaject may consider diversifying its supplier base and expanding its portfolio to include a broader range of formulations.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and commercialization of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet standards for safety, efficacy, and quality. For Indian pharmaceutical products, the FDA requires compliance with specific regulations, including the submission of New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for generics, as well as adherence to Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing for pharmaceutical products in the U.S. involves obtaining FDA approval, which includes the submission of appropriate applications (NDA or ANDA) and compliance with GMP standards. The FDA recognizes GMP certifications from various international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), provided they meet FDA requirements. Indian exporters seeking to supply Almaject and the broader U.S. market must ensure their manufacturing facilities are FDA-registered and compliant with these recognized GMP standards.

Quality & Labeling

Almaject Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Almaject's focus on generic injectable pharmaceuticals aligns with the growing demand for cost-effective injectable medications in the U.S. healthcare system. Therapeutic areas such as analgesics and antibiotics are critical in acute care settings, driving the importation of these products. The company's strategic emphasis on these categories enables it to address significant market needs, particularly in hospital and specialty care environments.

2Sourcing Profile

Almaject's sourcing strategy centers on generic injectable products, primarily sourced from India. This focus allows Almaject to leverage India's manufacturing capabilities, which are recognized for producing high-quality generic pharmaceuticals. By concentrating on injectables, Almaject aims to meet the specific needs of acute and alternate site healthcare markets in the U.S., ensuring a steady supply of essential medications.

3Market Positioning

Almaject serves the U.S. healthcare market by supplying generic injectable pharmaceuticals to acute and alternate site healthcare providers. Its product mix positions the company to cater to hospital and specialty care segments, where the demand for cost-effective injectable medications is substantial. By focusing on these segments, Almaject contributes to enhancing the accessibility and affordability of essential injectable therapies in the U.S. market.

Seller's Guide — How to Become a Supplier to Almaject Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

Almaject's current sourcing strategy, characterized by a concentrated supplier base, presents opportunities for new Indian suppliers to enter the U.S. market. By meeting FDA regulatory requirements and demonstrating consistent product quality, Indian exporters can establish partnerships with Almaject, potentially diversifying its supplier base and enhancing supply chain resilience. This diversification could lead to improved market competitiveness and reduced dependency on a single supplier.

2Requirements & Qualifications

Indian exporters aiming to supply Almaject and the U.S. market must ensure their manufacturing facilities are FDA-registered and compliant with recognized GMP standards, such as those from WHO or PIC/S. Additionally, they must adhere to FDA labeling requirements, including accurate and informative labeling in English. Compliance with these standards is essential for successful market entry and sustained business relationships.

3How to Approach

Frequently Asked Questions — Almaject Inc

What products does Almaject Inc import from India?

Almaject Inc imports 2 pharmaceutical products across 2 categories. Top imports: Ketorolac ($1.1M), Vancomycin ($950.0K).

Who supplies pharmaceuticals to Almaject Inc from India?

Almaject Inc sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $2.9M).

What is Almaject Inc's total pharmaceutical import value?

Almaject Inc's total pharmaceutical import value from India is $2.0M, based on 41 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Almaject Inc focus on?

Almaject Inc imports across 2 categories. The largest: Analgesics & Antipyretics (53.7%), Antibiotics (46.3%).

Get Full Almaject Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.